FDA Moves to Ban Compounded GLP-1 Drugs Semaglutide and Tirzepatide
The FDA proposes removing semaglutide, tirzepatide, and liraglutide from compounding lists, tightening access to cheaper GLP-1 alternatives.
Summary
The FDA is proposing to remove three major GLP-1 medications — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide — from the list of ingredients outsourcing facilities can use to make compounded drugs. This move effectively targets the booming market for compounded GLP-1 copies, which surged during drug shortages. Now that shortages of semaglutide and tirzepatide have been resolved, the FDA says there is no clinical justification for continued compounding. The agency cites concerns about unverifiable quality, safety, and efficacy in compounded versions. Major medical organizations support the crackdown. A public comment period runs through June 29, 2026.
Detailed Summary
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which governs what active ingredients outsourcing facilities can use to manufacture compounded medications in bulk. This regulatory action represents a significant escalation in the agency's effort to shut down the widespread market for compounded GLP-1 receptor agonists that emerged during a period of high demand and drug shortages.
GLP-1 drugs have become central to modern metabolic health management, with proven benefits for weight loss, blood sugar control, and increasingly, cardiovascular and longevity-related outcomes. Compounded versions offered a lower-cost alternative when brand-name supplies ran short, but the FDA argues that now shortages of semaglutide and tirzepatide have been resolved — in February 2025 and December 2024 respectively — there is no longer a legal or clinical basis for bulk compounding.
FDA Commissioner Marty Makary emphasized that compounding from bulk substances is only lawful when FDA-approved drugs are unavailable or when a clear clinical need exists. The agency's core concern is that compounded drugs bypass the rigorous approval process, meaning their potency, purity, and sterility cannot be independently verified. This raises real safety risks for patients using these products.
The American Medical Association, American Diabetes Association, and Endocrine Society have all voiced support for restricting compounded GLP-1 products. Notably, liraglutide remains on the shortage list, meaning its compounding status may be treated differently pending further review.
For health-conscious individuals currently using compounded GLP-1 medications for weight management or metabolic optimization, this proposal signals that access to these lower-cost alternatives may soon be significantly restricted. Patients should consult their prescribers about transitioning to FDA-approved formulations. The public comment window closes June 29, 2026, after which the FDA will finalize its decision.
Key Findings
- FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list.
- Shortages of semaglutide and tirzepatide are resolved, eliminating the primary legal basis for bulk compounding.
- Compounded GLP-1 drugs cannot be verified for quality, safety, or efficacy, posing patient safety risks.
- AMA, American Diabetes Association, and Endocrine Society all support restricting compounded GLP-1 products.
- Public comments on the FDA proposal are open through June 29, 2026.
Methodology
This is a regulatory news report from MedPage Today, a credible clinical news outlet targeting healthcare professionals. The article summarizes an official FDA proposal announcement and includes direct quotes from the FDA Commissioner. No original research data is presented; evidence basis is regulatory and policy-driven.
Study Limitations
This article is a brief news summary of a regulatory proposal, not a finalized rule — the outcome depends on public comment and FDA review. It does not address cost implications or insurance coverage for patients forced to switch to brand-name drugs. Independent verification of shortage resolution timelines and 503A pharmacy impacts is advisable.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.